{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:15:13Z","timestamp":1780568113542,"version":"3.54.1"},"reference-count":87,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research.<\/jats:p>","DOI":"10.3390\/ijms22136716","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:28:41Z","timestamp":1624447721000},"page":"6716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neurological Immunotoxicity from Cancer Treatment"],"prefix":"10.3390","volume":"22","author":[{"given":"Sarah F.","family":"Wesley","sequence":"first","affiliation":[{"name":"Multiple Sclerosis Center, Department of Neurology, Division of Neuroimmunology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center-New York Presbyterian Hospital, 710 W 168th Street, Neurological Institute, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Haggiagi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran T.","family":"Thakur","sequence":"additional","affiliation":[{"name":"Program in Neuroinfectious Diseases and Related Disorders, Division of Critical Care and Hospitalist Neurology, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"De Jager","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Department of Neurology, Division of Neuroimmunology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center-New York Presbyterian Hospital, 710 W 168th Street, Neurological Institute, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma: Clinical and Laboratory Research","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult. Scler. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lu, B.Y., Isitan, C., Mahajan, A., Chiang, V., Huttner, A., Mitzner, J.R., Wesley, S.F., and Goldberg, S.B. (2021). Intracranial complications from immune checkpoint therapy in a patient with non-small cell lung cancer and multiple sclerosis: Case report. JTO Clin. Res. Rep., 100183.","DOI":"10.1016\/j.jtocrr.2021.100183"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","first-page":"1493","article-title":"New Developments in the Treatment of Metastatic Melanoma: Immune Checkpoint Inhibitors and Targeted Therapies","volume":"34","author":"Azijli","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Shah","year":"2018","journal-title":"Ann. Intern Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2326-6066.CIR-13-0016","article-title":"Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production","volume":"1","author":"Poschke","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1756286418799864","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: What happens when you \u2019take the brakes off\u2019 the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ceca.2016.09.003","article-title":"Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate","volume":"60","author":"Joseph","year":"2016","journal-title":"Cell Calcium"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1038\/s41598-021-83612-3","article-title":"Ex vivo modelling of PD-1\/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.ejhg.5201767","article-title":"Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus","volume":"15","author":"Orozco","year":"2007","journal-title":"Eur. J. Hum. Genet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO.2016.34.15_suppl.3041","article-title":"Identification of somatic mutations to predict development of autoimmune adverse events to immune therapy in melanoma","volume":"34","author":"Wells","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/rheumatology\/41.2.180","article-title":"An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies","volume":"41","author":"Vaidya","year":"2002","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/dmrr.2552","article-title":"PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile","volume":"30","author":"Pizarro","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-019-0652-8","article-title":"Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach","volume":"11","author":"Khan","year":"2019","journal-title":"Genome Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41416-018-0074-1","article-title":"Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients","volume":"118","author":"Bins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrg.2015.33","article-title":"Autoimmune diseases\u2014Connecting risk alleles with molecular traits of the immune system","volume":"17","author":"Rich","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: A comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","article-title":"Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange","volume":"267","author":"Chung","year":"2020","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","article-title":"Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies","volume":"72","author":"Armangue","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_44","first-page":"7183747","article-title":"Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab","volume":"2019","author":"Lima","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1684\/ejd.2016.2943","article-title":"A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab","volume":"27","author":"Oishi","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-017-0249-y","article-title":"Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade","volume":"5","author":"Hench","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_51","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1159\/000368316","article-title":"Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma","volume":"37","author":"Lyons","year":"2014","journal-title":"Oncol. Res. Treat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.94.15_supplement.815","article-title":"A Case Report of Recurrent Longitudinally Extensive Holocord Transverse Myelitis After Combination Immune Checkpoint Inhibitor Therapy with Nivolumab and Ipilimumab (815)","volume":"94","author":"Brahmbhatt","year":"2020","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40425-018-0390-2","article-title":"Delayed onset of neurosarcoidosis after concurrent ipilimumab\/nivolumab therapy","volume":"6","author":"Tan","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000491599","article-title":"Neurosarcoidosis following Immune Checkpoint Inhibition","volume":"11","author":"Shah","year":"2018","journal-title":"Case Rep. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","article-title":"Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab","volume":"134","author":"Roberts","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition","volume":"21","author":"Pan","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mus.26070","article-title":"Neuromuscular complications of immune checkpoint inhibitor therapy","volume":"58","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_69","unstructured":"National Comprehensive Cancer Network (2021, May 14). Management of Immunotherapy-Related Toxicities. Version 3.2021. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in individualized management of chimeric antigen receptor T cell therapy","volume":"8","author":"Du","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_77","unstructured":"(2021, May 14). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human Services, NIH\/NCI, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/practneurol-2020-002550","article-title":"Neurotoxicity-CAR T-cell therapy: What the neurologist needs to know","volume":"20","author":"Neill","year":"2020","journal-title":"Pract. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:21:45Z","timestamp":1760163705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":87,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22136716"],"URL":"https:\/\/doi.org\/10.3390\/ijms22136716","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}